In the News

• Promising pre-clinical results for USask VIDO-InterVac COVID-19 vaccine

  May 25, 2020

  A COVID-19 vaccine candidate developed by VIDO-InterVac has cleared another major milestone in moving towards human clinical trials: the novel vaccine has proven highly effective in ferrets, one of the commonly used animal models for COVID-19.

• USask’s VIDO-InterVac and the National Research Council of Canada collaborate to advance development of vaccine against COVID-19

  May 12, 2020

  VIDO-InterVac and NRC announced a collaboration to accelerate the development and production of a candidate COVID-19 antigen in mammalian cells.

• ZYUS Collaborates with USask’s VIDO-InterVac to Develop a Plant-Based Vaccine for COVID-19

  May 7, 2020

  ZYUS Life Sciences Inc. and VIDO-InterVac will collaborate to test plant produced antigens in a vaccine for COVID-19.